Absorb GT1 Bioresorbable Vascular Scaffold System　― 1-Year Post-Marketing Surveillance in Japan ―-Reference-Cited by-同舟云学术

Absorb GT1 Bioresorbable Vascular Scaffold System　― 1-Year Post-Marketing Surveillance in Japan ―

Published:2019-11-25 Issue:12 Volume:83 Page:2460-2465
ISSN:1346-9843
Container-title:Circulation Journal
language:en
Short-container-title:Circ J

Author:

Suzuki Nobuaki¹,Kozuma Ken²,Nakamura Sunao³,Aramaki Kazuhiko⁴,Saito Shigeru⁵,Shibata Yoshisato⁶,Nanasato Mamoru⁷⁸,Fujii Kenshi⁹,Kusano Hajime¹⁰,Ediebah Divine¹⁰,Nakamura Masato¹¹

Affiliation:

1. Fourth Department of Internal Medicine, Teikyo University School of Medicine

2. Department of Medicine, Teikyo University School of Medicine

3. Department of Cardiology, Shin-Tokyo Hospital

4. Department of Cardiovascular Medicine, Saitama Sekishinkai Hospital

5. Department of Cardiovascular Medicine, Shonan Kamakura General Hospital

6. Department of Cardiovascular Medicine, Miyazaki Medical Association Hospital

7. Department of Second Cardiovascular Medicine, Red Cross Nagoya Daini Hospital

8. Department of Cardiovascular Medicine, Sakakibara Heart Institute

9. Department of Cardiovascular Medicine, Sakurabashi Watanabe Hospital

10. Abbott Vascular

11. Division of Cardiovascular Medicine, Toho University Ohashi Medical Center

Publisher

Japanese Circulation Society

Subject

Cardiology and Cardiovascular Medicine,General Medicine

Link

https://www.jstage.jst.go.jp/article/circj/83/12/83_CJ-19-0636/_pdf

Reference16 articles.

1. 1. Serruys PW, Onuma Y, Dudek D, Smits PC, Koolen J, Chevalier B, et al. Evaluation of the second generation of a bioresorbable everolimus-eluting vascular scaffold for the treatment of de novo coronary artery stenosis: 12-month clinical and imaging outcomes. J Am Coll Cardiol 2011; 58: 1578–1588.

2. 2. Serruys PW, Chevalier B, Dudek D, Cequier A, Carrie D, Iniguez A, et al. A bioresorbable everolimus-eluting scaffold versus a metallic everolimus-eluting stent for ischaemic heart disease caused by de-novo native coronary artery lesions ABSORB II: An interim 1-year analysis of clinical and procedural secondary outcomes from a randomised controlled trial. Lancet 2015; 385: 43–54.

3. 3. Kimura T, Kozuma K, Tanabe K, Nakamura S, Yamane M, Muramatsu T, et al. A randomized trial evaluating everolimus-eluting Absorb bioresorbable scaffolds vs. everolimus-eluting metallic stents in patients with coronary artery disease: ABSORB Japan. Eur Heart J 2015; 36: 3332–3342.

4. 4. Gao R, Yang Y, Han Y, Huo Y, Chen J, Yu B, et al. Bioresorbable vascular scaffolds versus metallic stents in patients with coronary artery disease: ABSORB China trial. J Am Coll Cardiol 2015; 66: 2298–2309.

5. 5. Ellis SG, Kereiakes DJ, Metzger DC, Caputo RP, Rizik DG, Teirstein PS, et al. Everolimus-eluting bioresorbable scaffolds for coronary artery disease. N Engl J Med 2015; 373: 1905–1915.

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The Absorb GT1 Bioresorbable Vascular Scaffold System　― 5-Year Post-Market Surveillance Study in Japan ―;Circulation Journal;2024-05-24

2. Less Is More: Developments in Nanotechnology for Antirestenosis Therapies;Arteriosclerosis, Thrombosis, and Vascular Biology;2023-07

3. Polymeric Materials, Advances and Applications in Tissue Engineering: A Review;Bioengineering;2023-02-06

4. Recent Least Burdensome Approach for the Approval of Innovative Medical Devices in Japan -Regulatory Approval Review of an Everolimus-eluting Bioresorbable Scaffold-;Internal Medicine;2021-01-15

5. Long-Term Outcomes of Absorb Bioresorbable Vascular Scaffold vs. Everolimus-Eluting Metallic Stent　― A Randomized Comparison Through 5 Years in Japan ―;Circulation Journal;2020-04-24